14/09/2026
Four days of science, conversations and new connections in Heidelberg!
From 9–12 September, IFPA joined the European Society for Dermatological Research (ESDR) Annual Meeting, bringing the patient perspective into one of Europe’s leading gatherings for dermatology research.
At our booth in the Patient Organizations Village, together with Anette Meyer, from Deutscher Psoriasis Bund e.V. (German Psoriasis Association), Raquel Vaz, representing IFPA, had the opportunity to meet researchers, healthcare professionals, patient organizations, partners and friends from around the world.
We had a chance to present IFPA's research and advocacy work for people living with psoriasis and psoriatic arthritis, and spread the word about the 8th World Psoriasis and Psoriatic Arthritis Conference ( ), taking place 20–22 May 2027 in Stockholm.
ESDR offered four packed days of research and discussion. Among the topics that caught our attention were new insights into generalized pustular psoriasis (GPP), genetic and environmental risk factors in psoriasis, and the latest research exploring how earlier treatment may influence the long-term course of psoriasis.
Another important discussion focused on the psychological and sexual health impact of psoriasis. While awareness among dermatologists is high, discussing these topics with patients remains a challenge.
We were also pleased to take part in this year’s International Psoriasis Council Research Incubator, bringing researchers together to explore topics within psoriasis and eczema and identify areas for future research.
Thank you to ESDR for a fantastic meeting and for making patient organizations such a valued part of the congress. And thanks to the patient organizations in the Village for the conversations, ideas and positive energy — including DEBRA International, Eczema UK, GlobalSkin, Pachyonychia Congenita Project and VIPOC, and especially our booth partners at Deutscher Psoriasis Bund e.V.
We leave Heidelberg with new knowledge, new connections and plenty of inspiration to bring back into our work for people living with psoriatic disease.